Generic competition holds back Dainippon Sumitomo
This article was originally published in Scrip
Dainippon Sumitomo Pharma (DSP)'s top product Amlodin (amlodipine, licensed from Pfizer) continues to be hit by generic competition, with sales of the calcium antagonist falling by 12% to ¥26.9 billion ($296 million) in the six months to September 30th. The product was opened up to its first generic entrants in Japan last year, and as one of the biggest-selling prescription drugs in the country has seen numerous alternative versions enter the market.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.